AN 1992:22038020 BIOTECHNO

AB The over-expression of the proto-oncogene HER-2 (c-erbB-2/neu) in ovarian, endometrial and mammary carcinoma is an important indicator for poor prognosis. We have previously shown in 3 out 4 ovarian carcinoma cell lines an interferon-gamma (IFN-γ)-mediated reduction in HER-2 specific protein and RNA levels. The oncogene expression was lowered only in the ovarian carcinoma cell lines but not in 3 IFN-γ-sensitive human breast cancer cell lines. We extended our observations also to IFN type I, α and ω. The expression of the oncogene was measured by both the p185(HER-2) ELISA and in selected cases by a living cell radioimmunoassay using the monoclonal antibody (MAb) 4D5 against the extracellular domain. Both IFN types reduced the expression of HER-2 in the ovarian carcinoma cell lines OVCAR-3, HTB-77, 2774 and SKOV-6, and in the SKUT-2 endometrial carcinoma cells. In contrast, SKOV-8 human ovarian carcinoma cells were sensitive for both IFN- types regarding proliferation, but only IFN-γ reduced proto-oncogene expression. In the SKBR-3 human mammary carcinoma cells, neither IFN- type had an effect on HER-2 expression. The **antibodies** 4D5, **7C2**, 3E8, and 3H4 which bind to the extracellular domain of p185(HER-2) protein specifically inhibited anchorage-independent growth of SKBR-3 and HTB-77 cells. Expression of the oncogene HER-2 is the leading prognostic factor in ovarian cancer. Its modulation might represent a mechanism by which IFN-s inhibit cell proliferation.

L10 ANSWER 3 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 1988:18169754 BIOTECHNO

TITLE: Rapid titration of bovine, caprine and human RS virus by a micro-immunoperoxidase assay using a monoclonal antibody and a permissive ovine kidney cell line

AUTHOR: Belanger F.; Alain R.; Payment P.; Lecomte J.; Trudel M.

CORPORATE SOURCE: Institut Armand-Frappier, Universite du Quebec, Centre de Recherche en Virologie, Ville de Laval, Que. H7N 4Z3, Canada.

SOURCE: Journal of Virological Methods, (1988), 20/2 (101-107) CODEN: JVMEDH ISSN: 0166-0934

DOCUMENT TYPE: Journal; Article

COUNTRY: Netherlands

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1988:18169754 BIOTECHNO

AB An indirect immunoperoxidase micro-assay, using a continuous cell line derived from ovine kidney cells (OK) and a previously characterized monoclonal **antibody** (**7C2**), specific for an exposed and highly conserved epitope of the fusion protein of different strains of RS virus, was used advantageously to rapidly titrate bovine, caprine and human strains of RSV by either quantal (TCID.sub.5.sub.0) or plaque forming assays. Virus titers, obtained in less than 36 h, were in agreement with those obtained by the conventional plaque assays which required an incubation period of 4 days or more. This assay is also applicable to micro-neutralization of fusion inhibition assays for testing serum or screening monoclonal antibodies.

L10 ANSWER 4 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1987:18019597 BIOTECHNO

TITLE: Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization

AUTHOR: Trudel M.; Nadon F.; Seguin C.; Payment P.; Talbot P.J.

CORPORATE SOURCE: Centre de Recherche en Virologie, Institute Armand-Frappier, Universite du Quebec, Ville de Laval, Que. H7N 4Z3, Canada.

SOURCE: Canadian Journal of Microbiology, (1987), 33/10 (933-938)
CODEN: CJMIAZ ISSN: 0008-4166
DOCUMENT TYPE: Journal; Article
COUNTRY: Canada
LANGUAGE: English
SUMMARY LANGUAGE: French; English
AN 1987:18019597 BIOTECHNO
AB Competition experiments and biological assays with a panel of 15 monoclonal antibodies confirmed the presence of a least four antigenic sites on the fusion protein of human respiratory syncytial virus, three of which were involved in virus neutralization. One antigenic site, recognized by two strongly neutralizing antibodies, was conserved after reduction and denaturation and shown by immunoblotting to be localized on the F.sub.1 fragment of the fusion protein. Cleavage of this protein with staphylococcal protease V8 or papain produced a series of smaller peptides from 11 to 7 kilodaltons that retained this important neutralization determinant. Compared with the other neutralization sites, the epitope defined by monoclonal **antibody 7C2** thus appears as the major neutralization epitope. Our peptide mapping results support the hypothesis that this major epitope is composed of a continuous sequence on the viral genome.

L10 ANSWER 5 OF 5 LIFESCI COPYRIGHT 2004 CSA on STN
ACCESSION NUMBER: 83:27789 LIFESCI
TITLE: A monoclonal antibody to kidney endopeptidase-24.11. Its application in immunoadsorbent purification of the enzyme and immunofluorescent microscopy of kidney and intestine.
AUTHOR: Gee, N.S.; Matsas, R.; Kenny, A.J.
CORPORATE SOURCE: Dep. Biochem., Univ. Leeds, Leeds LS2 9JT, UK
SOURCE: BIOCHEM. J., (1983) vol. 214, no. 2, pp. 377-386.
DOCUMENT TYPE: Journal
FILE SEGMENT: M; L
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Hybridoma methodology has been used to produce a monoclonal **antibody**, GK **7C2**, that binds specifically to microvillar endopeptidase-24.11 (EC 3.4.24.11). It was used to purify the enzyme from pig kidney. The enzyme had an apparent M sub(r) of 90,000 and contained endopeptidase activity sensitive to phosphoramidon. The identity was confirmed by immunoadsorbent purification of endopeptidase-24.11 by a column to which GK 7C2 had been attached. The endopeptidase, purified in a yield of 40%, was electrophoretically homogeneous and of specific activity comparable with that purified by other means. Fluorescence microscopy established that GK 7C2 bound specifically to the luminal membranes of kidney tubules and the intestinal mucosa. Thus endopeptidase-24.11 is located in the brush-border membranes of both cell types.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:50:30 ON 08 SEP 2004

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'AGRICOLA' ENTERED AT 16:50:48 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:50:48 ON 08 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:50:48 ON 08 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> (AMER5 or 7C2)(3A)antibody

L1	0	FILE AGRICOLA
L2	4	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	2	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES
L9 7 (AMER5 OR 7C2)(3A) ANTIBODY

=> dup rem
ENTER L# LIST OR (END):l9
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10 5 DUP REM L9 (2 DUPLICATES REMOVED)

=> d l10 ibib abs total

L10 ANSWER 1 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 1992:22179176 BIOTECHNO
TITLE: Radiolabeled antibody targeting of the HER-2/neu oncoprotein
AUTHOR: De Santes K.; Slamon D.; Anderson S.K.; Shepard M.; Fendly B.; Maneval D.; Press O.
CORPORATE SOURCE: University of Washington, Cancer Center, Mailstop RC-08,Seattle, WA 98195, United States.
SOURCE: Cancer Research, (1992), 52/7 (1916-1923)
CODEN: CNREA8 ISSN: 0008-5472
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1992:22179176 BIOTECHNO
AB The HER-2/neu oncogene encodes a M(r) 185,000 transmembrane phosphoglycoprotein which is overexpressed in 25-35% of breast and ovarian neoplasms and portends a poor prognosis. We have studied the feasibility of targeting this oncoprotein, designated p185, with radioiodinated murine monoclonal **antibodies** (muMABs) 4D5 and **7C2**, which recognize distinct epitopes on its extracellular domain. The rates of internalization and catabolism of these antibodies were analyzed by cellular radioimmunoassay and electron microscopy. After binding to NIH3T3 HER-2/neu cells, which show high surface expression of p185, the muMABs were endocytosed via coated pits, routed to lysosomes, and degraded. Approximately 44% of .sup.1.sup.2.sup.5I-4D5 and 39% of .sup.1.sup.2.sup.5I- 7C2 were catabolized by tumor cells after 24 h. The biodistribution of radiolabeled 4D5 and 7C2 were evaluated in beige/nude mice bearing s.c. NIH3T3 HER-2/neu grafts. A high specificity of localization was seen with tumor:organ ratios of activity generally ranging from 5:1 to 30:1. However, the percentage injected dose of radioactivity per gram of tumor declined sharply from 25% at 24 h to 5% at 120 h postinjection. Treating the animals with 400-700 μCi .sup.1.sup.3.sup.1I-4D5 caused a marked inhibition of tumor growth, although no mice were cured. Unlabeled 4D5 had no effect on tumor progression in this model, but administering 400-700 μCi of .sup.1.sup.3.sup.1I-DA4-4, an isotype- matched irrelevant muMAB, resulted in an intermediate degree of growth retardation. Analysis of kinetic blood data and whole-body time-activity curves indicated that the irrelevant conjugate remained in the body 2-3 times longer than .sup.1.sup.3.sup.1I-4D5. Radioiodinated anti-HER-2/neu muMABs are attractive agents for radioimmunodiagnosis and radioimmunotherapy of aggressive HER- 2/neu-positive breast and ovarian carcinomas, but effective strategies for retarding intratumoral catabolism may be necessary to optimize their clinical utility.

L10 ANSWER 2 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
ACCESSION NUMBER: 1992:22038020 BIOTECHNO
TITLE: Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells
AUTHOR: Marth C.; Cronauer M.V.; Doppler W.; Ofner D.; Ullrich A.; Daxenbichler G.
CORPORATE SOURCE: Dept. Obstetrics/Gynecology, Innsbruck University Clinic, Anichstrasse 35,A-6020 Innsbruck, Austria.
SOURCE: International Journal of Cancer, (1992), 50/1 (64-68)
CODEN: IJCNAW ISSN: 0020-7136
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1641cxc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS 16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:06:26 ON 08 SEP 2004

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:06:37 ON 08 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> HER2(3A)(ECD)(12A)antibody

L1	0	FILE AGRICOLA
L2	2	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	1	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES

L9	4	HER2(3A)(ECD)(12A) ANTIBODY

=> dup rem
ENTER L# LIST OR (END):l9
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9

L10	2	DUP REM L9 (2 DUPLICATES REMOVED)

=> d l10 ibib abs total

L10 ANSWER 1 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40 reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2000:30399203 BIOTECHNO
AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating **HER2 ECD** were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L10 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 1990:20263864 BIOTECHNO
TITLE: ELISA for quantitation of the extracellular domain of p185(HER2) in biological fluids
AUTHOR: Sias P.E.; Kotts C.E.; Vetterlein D.; Shepard M.; Wong W.L.T.
CORPORATE SOURCE: Immunology Research and, Assay Technologies, Genentech Inc., 460 Point San Bruno Boulevard,South San Francisco, CA 94080, United States.
SOURCE: Journal of Immunological Methods, (1990), 132/1 (73-80)

CODEN: JIMMBG ISSN: 0022-1759
DOCUMENT TYPE: Journal; Article
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1990:20263864 BIOTECHNO
AB The HER2/neu proto-oncogene encodes a receptor that belong to the tyrosine-specific protein kinase family. Amplification of the HER2 gene in patients with breast and ovarian cancer has been shown to predict poorer survival rates. In order to understand the role of HER2 in malignant and normal cells, it is necessary to devise assays that can quantitate expression levels of the HER2 gene product (p185(HER2)) in production samples, biopsy specimens and biological fluids. We have developed a simple, quantitative ELISA that uses two monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185(**HER2**) (**HER2 ECD**). The assay has a detection range of 0.25-120 ng/ml, is precise and sensitive. The ability of this assay to detect biologically active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay (r = 0.92). The sandwich ELISA can also accurately quantitate rHER2 ECD in mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as antigen for immunotherapy and in patients which 'shed' receptor.

TITLE: Increased levels of circulating **HER2 ECD** in response to anti-HER2 **antibody** therapy.

AUTHOR(S): Park, J. W. [Reprint author]; Colbern, G.; Nuijens, A.; Baselga, J.; McMillan, A.; Henderson, I. C.; Papahadjopoulos, D.; Benz, C. C.

CORPORATE SOURCE: UCSF, San Francisco, CA 94143, USA

SOURCE: Breast Cancer Research and Treatment, (Oct., 1997) Vol. 46, No. 1, pp. 67. print.
Meeting Info.: 20th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA. December 3-6, 1997.
CODEN: BCTRD6. ISSN: 0167-6806.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 30 Jan 1998
Last Updated on STN: 30 Jan 1998

L26 ANSWER 3 OF 4 DUPLICATE 1 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 1997:33318 BIOSIS

DOCUMENT NUMBER: PREV199799339721

TITLE: 186-Re-labeled antibodies to p185-HER2 as HER2-targeted radioimmunopharmaceutical agents: Comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

AUTHOR(S): Kotts, C. E. [Reprint author]; Su, F. M.; Leddy, C.; Dodd, T.; Scates, S.; Shalaby, M. R.; Wirth, C. M.; Giltinan, D.; Schroff, R. W.; Fritzberg, A. R.; Shepard, H. M.; Slamon, D. J.; Hutchins, B. M.

CORPORATE SOURCE: Genentech Inc., Mail Zone 65, 460 Point San Bruno Blvd., S. San Francisco, CA 94080, USA

SOURCE: Cancer Biotherapy and Radiopharmaceuticals, (1996) Vol. 11, No. 2, pp. 133-144.
ISSN: 1084-9785.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 28 Jan 1997
Last Updated on STN: 28 Jan 1997

AB Overexpression of the HER2/neu protooncogene has been shown to correlate with poor clinical prognosis. A murine monoclonal **antibody** (4D5) directed against the extracellular domain (**ECD**) of p185-**HER2** has been shown to inhibit in vitro and in vivo growth of carcinomas overexpressing HER2 and has been humanized (rhuMAb HER2). The objective of the study was the identification of an agent which might be useful for in vitro studies, tumor imaging and/or radioimmunotherapy by linking beta-emitting radionuclides to these HER2-targeted antibodies. Murine 4D5 and humanized rhuMAb HER2 were radiolabeled with 125I, 131I or 186Re. Physical characteristics (TCA precipitability, SDS-PAGE, size exclusion chromatography), binding affinities to the HER2 ECD (in an ELISA and on SK-BR-3 cells) and antiproliferative activities of the radiolabeled antibodies were determined. Although 131I-4D5 and 131I-rhuMAb HER2 usually retained gt 85% ECD binding, they exhibited increased aggregation and fragment content, drastically reduced antiproliferative activities and poor stability upon storage at 4 degree C. For these antibody preparations, conservation of binding did not necessarily correlate with preservation of bioactivity indicating the importance of bioactivity determinations in radiolabeled antibody studies. Conversely, 4D5 and rhuMAb HER2 labeled with 125I or 186Re maintained physical properties, ECD binding, antiproliferative activities and were stable upon storage at 4 degree C for at least 8 days. The superior retention of physical and biological characteristics of 186Re-labeled 4D5 and rhuMAb HER2 compared with their 131I-labeled counterparts suggests the potential for their use as radioimaging and radioimmunotherapeutic agents in the treatment of HER2

=> dup rem
ENTER L# LIST OR (END):l20-23
PROCESSING COMPLETED FOR L20
PROCESSING COMPLETED FOR L21
PROCESSING COMPLETED FOR L22
PROCESSING COMPLETED FOR L23
L26 4 DUP REM L20-23 (3 DUPLICATES REMOVED)

=> d l26 ibib abs total

L26 ANSWER 1 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
ACCESSION NUMBER: 2000217009 EMBASE
TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain. rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000) 6/6 (2356-2362).
Refs: 40
ISSN: 1078-0432 CODEN: CCREF4
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
022 Human Genetics
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

Date

AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating **HER2 ECD** were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L26 ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
ACCESSION NUMBER: 1998:69783 BIOSIS
DOCUMENT NUMBER: PREV199800069783

overexpressing tumors.

L26 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 1990:568423 CAPLUS
DOCUMENT NUMBER: 113:168423
TITLE: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
AUTHOR(S): Sias, Patricia E.; Kotts, Claire E.; Vetterlein, David; Shepard, Mike; Wong, Wai Lee T.
CORPORATE SOURCE: Dep. Immunol., Genentech Inc., So., San Francisco, CA, 94080, USA
SOURCE: Journal of Immunological Methods (1990), 132(1), 73-80
CODEN: JIMMBG; ISSN: 0022-1759
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The HER2/neu proto-oncogene encodes a receptor that belongs to the tyrosine-specific protein kinase family. A simple, quant. ELISA was developed that uses 2 monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185HER2 (**HER2 ECD**). The assay has a detection range of 0.25-120 ng/mL, is precise and sensitive. The ability of this assay to detect biol. active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay. The sandwich ELISA can also accurately quantitate rHER2 ECD in a mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as an antigen for immunotherapy and in patients which shed receptor.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:06:26 ON 08 SEP 2004

=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:06:37 ON 08 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:06:37 ON 08 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> HER2(3A)(ECD)(12A)antibody

L1	0	FILE AGRICOLA
L2	2	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	1	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES

L9	4	HER2(3A)(ECD)(12A) ANTIBODY

=> dup rem
ENTER L# LIST OR (END):l9
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9

L10	2	DUP REM L9 (2 DUPLICATES REMOVED)

=> d l10 ibib abs total

L10 ANSWER 1 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40 reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2000:30399203 BIOTECHNO
AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating **HER2 ECD** were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L10 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 1990:20263864 BIOTECHNO
TITLE: ELISA for quantitation of the extracellular domain of p185(HER2) in biological fluids
AUTHOR: Sias P.E.; Kotts C.E.; Vetterlein D.; Shepard M.; Wong W.L.T.
CORPORATE SOURCE: Immunology Research and, Assay Technologies, Genentech Inc., 460 Point San Bruno Boulevard,South San Francisco, CA 94080, United States.
SOURCE: Journal of Immunological Methods, (1990), 132/1 (73-80)

CODEN: JIMMBG ISSN: 0022-1759
DOCUMENT TYPE: Journal; Article
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1990:20263864 BIOTECHNO
AB The HER2/neu proto-oncogene encodes a receptor that belong to the tyrosine-specific protein kinase family. Amplification of the HER2 gene in patients with breast and ovarian cancer has been shown to predict poorer survival rates. In order to understand the role of HER2 in malignant and normal cells, it is necessary to devise assays that can quantitate expression levels of the HER2 gene product (p185(HER2)) in production samples, biopsy specimens and biological fluids. We have developed a simple, quantitative ELISA that uses two monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185(**HER2**) (**HER2 ECD**). The assay has a detection range of 0.25-120 ng/ml, is precise and sensitive. The ability of this assay to detect biologically active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay (r = 0.92). The sandwich ELISA can also accurately quantitate rHER2 ECD in mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as antigen for immunotherapy and in patients which 'shed' receptor.

=> file .chemistry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.38	11.59

FILE 'CAPLUS' ENTERED AT 16:10:42 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 16:10:42 ON 08 SEP 2004
Compendex Compilation and Indexing (C) 2004
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (c) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 16:10:42 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> HER2(3A)(ECD)(12A)antibody

L11	1	FILE CAPLUS
L12	2	FILE BIOTECHNO
L13	0	FILE COMPENDEX
L14	0	FILE ANABSTR
L15	0	FILE CERAB
L16	0	FILE METADEX
L17	16	FILE USPATFULL

TOTAL FOR ALL FILES
L18 19 HER2(3A)(ECD)(12A) ANTIBODY

=> dup rem
ENTER L# LIST OR (END):l18
PROCESSING COMPLETED FOR L18
L19 18 DUP REM L18 (1 DUPLICATE REMOVED)

=> d l19 ibib abs total

L19 ANSWER 1 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:90568 USPATFULL
TITLE: Method for making humanized antibodies
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6719971	B1	20040413
APPLICATION INFO.:	US 2000-705392		20001102 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 146206, now patented, Pat. No. US 6407213, issued on 18 Jun 2002 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ungar, Susan
ASSISTANT EXAMINER: Davis, Minh Tam
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 4948
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:288214 USPATFULL
TITLE: Protein formulation
INVENTOR(S): Andya, James, Millbrae, CA, UNITED STATES
Cleland, Jeffrey L., San Carlos, CA, UNITED STATES
Hsu, Chung C., Los Altos Hills, CA, UNITED STATES
Lam, Xanthe M., San Francisco, CA, UNITED STATES
Overcashier, David E., El Granada, CA, UNITED STATES
Shire, Steven J., Belmont, CA, UNITED STATES
Yang, Janet Yu-Feng, San Mateo, CA, UNITED STATES
Wu, Sylvia Sau-Yan, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202972	A1	20031030
APPLICATION INFO.:	US 2003-428728	A1	20030502 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-809511, filed on 14 Mar 2001, PENDING Continuation of Ser. No. US 1996-615369, filed on 14 Mar 1996, GRANTED, Pat. No. US 6267958

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-29182P	19950727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:266208 USPATFULL
TITLE: Antibody fusion proteins: effective adjuvants of protein vaccination
INVENTOR(S): Penichet, Manuel L., Los Angeles, CA, UNITED STATES
Dela Cruz, Jay, Inglewood, CA, UNITED STATES
Peng, Lisan, Tuscon, AZ, UNITED STATES
Morrison, Sherie L., Los Angeles, CA, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003187225	A1	20031002	
APPLICATION INFO.:	US 2002-118473	A1	20020405	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-366917P	20020321 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:245137 USPATFULL
TITLE: CHIMERIC ANTIBODY FUSION PROTEINS FOR THE RECRUITMENT AND STIMULATION OF AN ANTITUMOR IMMUNE RESPONSE
INVENTOR(S): ROSENBLATT, JOSEPH D., ROCHESTER, NY, UNITED STATES

CHALLITA-EID, PIA, ROCHESTER, NY, UNITED STATES
MORRISON, SHERIE, LOS ANGELES, CA, UNITED STATES
ABBOUD, CAMILLE N., ROCHESTER, NY, UNITED STATES
SHIN, SEUNG-UON, LOS ANGELES, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171551	A1	20030911
APPLICATION INFO.:	US 1998-16743	A1	19980130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-37256P	19970131 (60)
	US 1997-64018P	19971103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL L GOLDMAN ESQ, NIXON PEABODY LLP, CLINTON SQUARE, P O BOX 1051, ROCHESTER, NY, 14603
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 2604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to chimeric molecules for the stimulation of an anti-tumor immune response to facilitate immune eradication of breast, ovarian and other cancer cells. The chimeric molecules include a binding region which specifically binds to a tumor specific antigen and a chemokine and/or costimulatory ligand. The invention further provides methods for inducing a tumor specific immune response and compositions which can be administered to mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:244864 USPATFULL
TITLE: Compounds that bind HER2
INVENTOR(S): Dennis, Mark S., San Carlos, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171278	A1	20030911
APPLICATION INFO.:	US 2002-196394	A1	20020715 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-609721, filed on 30 Jun 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142232P	19990702 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 3598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the novel compounds of the invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as for their use in

research, diagnostic, therapeutic, and prophylactic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:225711 USPATFULL
TITLE: Cell and tissue arrays and microarrays and methods of use
INVENTOR(S): Frantz, Gretchen, San Francisco, CA, UNITED STATES
Landon, Trent Harris, San Francisco, CA, UNITED STATES
Peale,, Franklin V., JR., San Carlos, CA, UNITED STATES
Pham, Thinh Quang, San Bruno, CA, UNITED STATES
Stephan, Jean Philippe F., San Carlos, CA, UNITED STATES
Dunlap, Debra Y., Sunnyvale, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003157523	A1	20030821	
APPLICATION INFO.:	US 2002-300546	A1	20021120	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-393551P	20020702	(60)
	US 2002-389610P	20020617	(60)
	US 2002-359563P	20020222	(60)
	US 2002-355205P	20020207	(60)
	US 2001-332635P	20011121	(60)
	US 2001-332293P	20011120	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 160
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 4103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to biological arrays, biological microarrays, and methods of using the arrrays and microarrays to detect the amount and/or presence of a biological molecule in a biological sample. Biological arrays of the invention comprise a solidified, sectionable matrix comprising a plurality of wells disposed therein and one or more biological samples disposed within the plurality of wells, which biological arrays optionally comprise an internal standard preparation and/or an orientation marker. Sections or slices of the biological arrays are mounted on a planar substrate surface to form cellular microarrays of the invention. In alternative cellular microarrays of the invention, the matrix material is a temperature-sensitive material removable from the microarray leaving cellular biological material on the substrate surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:225308 USPATFULL
TITLE: Methods for diagnosis and therapy of hematological and virus-associated malignancies
INVENTOR(S): Gaiger, Alexander, Seattle, WA, UNITED STATES
Cheever, Martin A., Mercer Island, WA, UNITED STATES
Hand-Zimmermann, Susan, Redmond, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157119	A1	20030821
APPLICATION INFO.:	US 2002-313644	A1	20021204 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-675904, filed on 28 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-638280, filed on 14 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-404443, filed on 22 Sep 1999, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:285299 USPATFULL
TITLE: Method for making humanized antibodies
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6639055	B1	20031028
APPLICATION INFO.:	US 2000-705686		20001102 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 146206, now patented, Pat. No. US 6407213 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Helms, Larry R
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 4651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:171913 USPATFULL
TITLE: Analytical method
INVENTOR(S): Ralph, Peter, Orinda, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002090662	A1	20020711
APPLICATION INFO.:	US 2001-921161	A1	20010801 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225433P	20000815 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:8587 USPATFULL
TITLE: Multivalent antibodies and uses therefor
INVENTOR(S): Miller, Kathy L., San Francisco, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004587	A1	20020110
APPLICATION INFO.:	US 2001-813341	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195819P	20000411 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Attn: Wendy M. Lee, 1 DNA Way, South San Francisco, CA, 94080-4990
NUMBER OF CLAIMS: 93
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Page(s)
LINE COUNT: 4913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:144366 USPATFULL
TITLE: Method for making humanized antibodies
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6407213	B1	20020618
APPLICATION INFO.:	US 1993-146206		19931117 (8)
	WO 1992-US5126		19920615

19931117 PCT 371 date
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Davis, Minh-Tam
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 82
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 4467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2001:133877 USPATFULL
TITLE: Protein formulation
INVENTOR(S): Andya, James, Millbrae, CA, United States
Cleland, Jeffrey L., San Carlos, CA, United States
Hsu, Chung C., Los Altos Hills, CA, United States
Lam, Xanthe M., San Francisco, CA, United States
Overcashier, David E., El Granada, CA, United States
Shire, Steven J., Belmont, CA, United States
Yang, Janet Yu-Feng, San Mateo, CA, United States
Wu, Sylvia Sau-Yan, San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014326	A1	20010816
	US 6685940	B2	20040203
APPLICATION INFO.:	US 2001-809511	A1	20010314 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-615369, filed on 14 Mar 1996, PENDING Continuation of Ser. No. US 1995-508014, filed on 27 Jul 1995, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-29182P	19960729 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2001:121066 USPATFULL
TITLE: Protein formulation
INVENTOR(S): Andya, James, Millbrae, CA, United States
Cleland, Jeffrey L., San Carlos, CA, United States
Hsu, Chung C., Los Altos Hills, CA, United States
Lam, Xanthe M., San Francisco, CA, United States
Overcashier, David E., El Granada, CA, United States
Shire, Steven J., Belmont, CA, United States
Yang, Janet Yu-Feng, San Mateo, CA, United States
Wu, Sylvia Sau-Yan, San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267958	B1	20010731
APPLICATION INFO.:	US 1996-615369		19960314 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-29182P	19960727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: DiBrino, Marianne
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 14 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2000:50547 USPATFULL
TITLE: Humanized antibodies and methods for making them
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054297		20000425
APPLICATION INFO.:	US 1995-437642		19950509 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-934373, filed on 21 Aug 1992, now patented, Pat. No. US 5821337, issued on 13 Oct 1998 which is a continuation-in-part of Ser. No. WO 1992-US5126, filed on 15 Jun 1992 which is a continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Reeyes, Julie E
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 5670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 18 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40 reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2000:30399203 BIOTECHNO
AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating **HER2 ECD** were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower (P = 0.021) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; P = 0.035). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L19 ANSWER 16 OF 18 USPATFULL on STN

ACCESSION NUMBER: 1998:124659 USPATFULL
TITLE: Immunoglobulin variants
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5821337		19981013
APPLICATION INFO.:	US 1992-934373		19920821 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Davis, Minh-Tam
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 3
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 4813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 18 USPATFULL on STN
ACCESSION NUMBER: 97:61573 USPATFULL
TITLE: Expression of functional antibody fragments
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648237		19970715
APPLICATION INFO.:	US 1995-433781		19950503 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-291323, filed on 16 Aug 1994, now abandoned which is a continuation of Ser. No. US 1991-762292, filed on 19 Sep 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Lucas, John
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1,19
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab' and F(ab').sub.2 antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 1990:568423 CAPLUS
DOCUMENT NUMBER: 113:168423
TITLE: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
AUTHOR(S): Sias, Patricia E.; Kotts, Claire E.; Vetterlein, David; Shepard, Mike; Wong, Wai Lee T.
CORPORATE SOURCE: Dep. Immunol., Genentech Inc., So., San Francisco, CA, 94080, USA
SOURCE: Journal of Immunological Methods (1990), 132(1), 73-80
CODEN: JIMMBG; ISSN: 0022-1759
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The HER2/neu proto-oncogene encodes a receptor that belongs to the tyrosine-specific protein kinase family. A simple, quant. ELISA was developed that uses 2 monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185HER2 (**HER2 ECD**). The assay has a detection range of 0.25-120 ng/mL, is precise and sensitive. The ability of this assay to detect biol. active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay. The sandwich ELISA can also accurately quantitate rHER2 ECD in a mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as an antigen for immunotherapy and in patients which shed receptor.

=> file .jacob

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.49	58.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.70	-0.70

FILE 'CAPLUS' ENTERED AT 16:13:06 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:13:06 ON 08 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'MEDLINE' ENTERED AT 16:13:06 ON 08 SEP 2004

FILE 'EMBASE' ENTERED AT 16:13:06 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 16:13:06 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> HER2(3A)(ECD)(12A)antibody
L20 1 FILE CAPLUS
L21 2 FILE BIOSIS
L22 1 FILE MEDLINE
L23 3 FILE EMBASE
L24 16 FILE USPATFULL

TOTAL FOR ALL FILES
L25 23 HER2(3A)(ECD)(12A) ANTIBODY